How much does EVRYSDI cost?

Pricing for EVRYSDI varies by insurance plan, dose, and pharmacy. Our database does not show a fixed cost because prices change faster than we can verify. For current pharmacy prices, check your insurance's formulary tier (in the prior-authorization section), use the GoodRx or Cost Plus Drugs deep links on this page, or ask your pharmacist to run a test claim. If a copay card is listed, it usually drops the out-of-pocket significantly for commercial insurance.

Does EVRYSDI need prior authorization?

EVRYSDI appears on 1 payer formulary in our database. PA requirements vary by payer — see the prior-authorization table on this page for specifics. In general, specialty and brand-name drugs are more likely to require PA than generic equivalents.

Is there a copay card or patient assistance program for EVRYSDI?

We haven't verified an active copay card or PAP for EVRYSDI in our current data. Check NeedyMeds or RxAssist for independent directories, or submit what you find via our "Report a broken link" form.

What is EVRYSDI used to treat?

EVRYSDI (generic: Risdiplam) is indicated for Spinal Muscular Atrophy. Click any condition name on this page for more detail.

Does EVRYSDI have a generic version?

The generic name for EVRYSDI is Risdiplam. Whether a generic is currently available depends on patent status — check the FDA Orange Book or ask your pharmacist. Generics are often substantially cheaper than brand-name drugs.

EVRYSDI

Generic: Risdiplam

Data may be stale·Apr 23, 2026

Manufacturer: Genentech
NDC: 50242-175
RxCUI: 2390940
Route: ORAL
ICD-10 indication: G12.1

Affordability Check

How much will you actually pay for EVRYSDI?

In 30 seconds, see every legitimate way to afford EVRYSDI — Medicare copay, manufacturer copay card, Patient Assistance Program, grants, or cash.

Check my options →

About EVRYSDI

What is this medication?

Evrysdi is a prescription medicine used to treat spinal muscular atrophy, commonly known as SMA, in both adults and children. SMA is a rare genetic disorder that affects the nerve cells in the spinal cord, leading to progressive muscle weakness and loss of movement. This medication works by helping the body produce more of the survival motor neuron protein, which is vital for the health and survival of the nerve cells that control muscle movement.

This treatment is a liquid medication that is taken once daily by mouth or through a feeding tube, making it the first at-home oral therapy for this condition. It is approved for use in patients of all ages, including infants. By increasing the levels of necessary proteins throughout the central nervous system and the rest of the body, Evrysdi aims to improve motor function and help individuals with SMA maintain their physical strength and independence.

Copay & patient assistance

Patient Copay Amount: As little as $0 per 30-day supply
Maximum Annual Benefit Limit: Up to $25,000 per calendar year
Core Eligibility Restrictions: Must have commercial (private or non-governmental) insurance; not eligible if prescriptions are reimbursed under any federal, state, or government-funded insurance programs (e.g., Medicare, Medicaid, TRICARE, VA, etc.); must have a valid prescription for an FDA-approved indication; must be 18 years of age or older (or have a legal guardian over 18 to manage the program); must live and receive treatment in the United States or U.S. Territories; cannot be receiving assistance through the Genentech Patient Foundation or any other charitable organization for the same expenses.
RxBIN, PCN, and Group numbers: Not Publicly Available

External links go directly to the manufacturer's portal. RxCopays does not receive compensation for referrals.

Compare pricing elsewhere

RxCopays doesn't sell drugs or take referral fees. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary.

Cost Plus Drug Company

Mark Cuban's transparent-pricing pharmacy — manufacturer cost + 15% markup + $5 dispensing fee. No insurance needed. Search alphabetically for Risdiplam.

Browse Cost Plus medications →

GoodRx

Compare local pharmacy prices with GoodRx coupons. Use the price with your insurance or without — whichever is cheaper.

Lookup EVRYSDI →

NeedyMeds

Independent nonprofit directory of patient assistance programs, copay cards, and charity co-pay foundations.

Search for Risdiplam →

RxAssist

PAP directory maintained by Volunteers in Health Care at Brown University. Free, no ads.

Search PAPs →

We deep-link because transparency helps patients. None of these partners pay RxCopays.

Conditions we've indexed resources for

Click a condition to see copay cards, grants, and PA rules specific to it. For the full list of FDA-approved indications, see Prescribing information above.

Spinal Muscular AtrophyRare

Medicare Part D coverage

How EVRYSDI appears across Medicare Part D plan formularies nationally. Source: CMS monthly Prescription Drug Plan file (2026-08-31).

Covered by plans

515 of 5,499 plans

Most common tier

Tier 5

On 75% of covering formularies

Prior authorization required

99%

of covering formularies

Tier	Formularies on this tier	Share
Tier 1 (preferred generic)	19	22%
Tier 4 (non-preferred brand)	2	2%
Tier 5 (specialty)	65	75%
Tier 6	1	1%

Step therapy: 0% of formularies

Quantity limits: 69% of formularies

Coverage breadth: 87 of 65 formularies

How to read this:plans on the same formulary share tier + PA rules. Your specific plan's copay depends on (a) the tier above, (b) your plan's cost-share for that tier, (c) whether you're in the initial coverage phase or past the 2026 $2,000 out-of-pocket cap. For your exact plan, check its Summary of Benefits or log in to your Medicare.gov account. Copay cards don't apply to Medicare (federal law).

Prior authorization & coverage

Payer	PA	Step therapy	Copay tier
— Medicare Part D	—	—	—

Payer

Step therapy

Copay tier

—

Medicare Part D

—

Related drugs

How this page is sourced

Drug identity verified against openFDA NDC Directory.
Label text (when shown) originates from NLM DailyMed.
Copay and assistance URLs verified periodically; if you hit a broken link, tell us.

Rare-disease navigation (specialists, trials, patient communities)

EVRYSDI treats a rare condition. For in-depth disease pages on our sister site:

UniteRare · Spinal Muscular Atrophy

UniteRare.org is our sister site for rare-disease navigation — same editorial team, same accuracy standards.